Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Steroid-Free hope for arthritis patients?

NCT ID NCT02997605

Disease control Sponsor: University Hospital, Toulouse Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested two methods to help people with rheumatoid arthritis stop taking steroids (prednisone) safely. 102 adults with low disease activity or remission were given either a gradual dose reduction or a replacement with hydrocortisone. The goal was to see which approach allowed more patients to stop steroids completely after one year without causing adrenal gland problems.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Prednisone and Hydrocortisone
What this could lead to
If successful, this could help rheumatoid arthritis patients stop taking steroids safely without causing adrenal insufficiency.
What could go wrong
This is a small Phase 4 trial with only 102 participants, so results may not apply to everyone. The strategies may not work for all patients, and there is a risk of adrenal insufficiency during withdrawal.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

102 people

The number who actually took part.

Started

Jan 2017

Finished

Jan 2022

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patients ≥ 18 years old. * Fulfilling the 2010 American College of Rheumatology (ACR)/EULAR criteria for RA. * Treated with a stable dose of Synthetic Disease Modifying Anti-Rheumatic Drugs (sDMARD) or Biological Disease Modifying Anti-Rheumatic Drug (bDMARD) for at least 3 months. * Who have been treated with prednisone or prednisolone for at least 6 months. * With a stable dose of prednisone or prednisolone of 5mg/day for at least 3 months. * With a DAS28 ≤3.2 for at least 3 months. * Patients with health insurance * Patients who have signed a written informed consent form. Exclusion Criteria: * Any chronic condition that would need long term corticoid use (e.g. chronic lung diseases). * Evidence of a flare within the last 3 months. * Evidence of an allergy or intolerance to hydrocortisone or prednisone. * Chronic idiopathic, or autoimmune clinical adrenal insufficiency. * GC joint injections within the last 3 months or scheduled in the next 3 months. * Any GC intake expected more than \>5mg/day within the next 12 months. * Association with sultopride and with live vaccines * Significant trauma or major surgery within the 3 months prior to the baseline visit. * Scheduled surgery in the next 12 months. * Fibromyalgia. * Foreseeable poor compliance with the strategy. * Patient with any condition that would prevent participation in the study and completion of the study procedures, including language limitation. * Alcohol and/or drug misuse as determined by the investigator. * Pregnancy or breastfeeding. * Patient is not willing to sign the informed consent. * Juridical Protection * DAS28\>3.2 after one month of a stable dose of prednisone 5 mg/day.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Rheumatoid arthritis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

rheumatoid arthritis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Rheumatoid arthritis

Contacts and locations

Locations

  • Bichat Hospital

    Paris, France

  • Bicêtre Hospital

    Le Kremlin-Bicêtre, France

  • Bordeaux University Hospital

    Bordeaux, France

  • Brest University Hospital

    Brest, France

  • Clermont-Ferrand Hospital

    Clermont-Ferrand, France

  • Cochin Hospital

    Paris, France

  • Hospital Pierre-Paul Riquet

    Toujouse, 31059, France

  • Jean Rougier Hospital

    Cahors, France

  • La Pitié-Salpétrière

    Paris, France

  • Lille Hospital

    Lille, France

  • Limoges Hospital

    Limoges, France

  • Lyon Sud Hopsital

    Pierre-Bénite, France

  • Montpellier Hospital

    Montpellier, France

  • Orléans Hospital

    Orléans, France

  • Pasteur Hospital

    Nice, France

  • Saint-Etienne Hospital

    Saint-Etienne, France

  • Strasbourg Hospital

    Strasbourg, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.